4.8 Article

CD47 cross-dressing by extracellular vesicles expressing CD47 inhibits phagocytosis without transmitting cell death signals

期刊

ELIFE
卷 11, 期 -, 页码 -

出版社

eLIFE SCIENCES PUBL LTD
DOI: 10.7554/eLife.73677

关键词

CD47; macrophages; extracellular vesicles; exosomes; xenotransplantation; tumor cells; None

类别

资金

  1. NIH
  2. First Hospital of Jilin University
  3. NIH Shared Instrumentation Grant
  4. [PO1 AI045897]
  5. [1S10RR027050]

向作者/读者索取更多资源

CD47 cross-dressing provides an alternative source of cell surface CD47 that can elicit its anti-phagocytic function without inducing cell death, suggesting a new approach to optimize CD47 transgenic method.
Transgenic CD47 overexpression is an encouraging approach to ameliorating xenograft rejection and alloresponses to pluripotent stem cells, and the efficacy correlates with the level of CD47 expression. However, CD47, upon ligation, also transmits signals leading to cell dysfunction or death, raising a concern that overexpressing CD47 could be harmful. Here, we unveiled an alternative source of cell surface CD47. We showed that extracellular vesicles, including exosomes, released from normal or tumor cells overexpressing CD47 (transgenic or native) can induce efficient CD47 cross-dressing on pig or human cells. Like the autogenous CD47, CD47 cross-dressed on cell surfaces is capable of interacting with SIRP alpha to inhibit phagocytosis. However, ligation of the autogenous, but not cross-dressed, CD47 induced cell death. Thus, CD47 cross-dressing provides an alternative source of cell surface CD47 that may elicit its anti-phagocytic function without transmitting harmful signals to the cells. CD47 cross-dressing also suggests a previously unidentified mechanism for tumor-induced immunosuppression. Our findings should help to further optimize the CD47 transgenic approach that may improve outcomes by minimizing the harmful effects of CD47 overexpression.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.8
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据